CSPG4 and head and neck cancer: Furthermore, a CAR-T cell therapy targeting CSPG4 is currently used in a phase I clinical trial for head and neck cancer (NCT06096038) [34], suggesting CSPG4-targeting CARs are specific with minimal off-target effects.